Apalutamide can cause seizures. Avoid activities that could be dangerous if you have an unexpected seizure.【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 228
Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 220
Apalutamide is an oral anti-androgen medication, mainly used to treat non-metastatic or metastatic castration-resistant prostate cancer. It delays tum···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 208
FDA Approval AnnouncementFebruary 14, 2018 -- The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 210
FDA Approval AnnouncementHORSHAM, Pa., Sept. 17, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today th···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 208
KRAS mutations have been considered a major challenge in cancer research, remaining difficult to overcome for many years. The introduction of Sotorasi···【Read More】
Update: 2026-03-04Source: Haiou HealthViews: 204
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021.I.···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 219
In 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib for the treatment of certain adult patients with non-sm···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 214
Sotorasib is an oral targeted anticancer drug developed by Amgen, a small molecule inhibitor specifically targeting the KRAS G12C mutation.Indications···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 215
On June 13, 2024, Bristol-Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib fo···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 172
On November 16, 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved ripretinib (Augtyro) for the treatm···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 194
Ripretinib (Augtyro) is a next-generation targeted anticancer drug developed by Bristol-Myers Squibb (BMS), offering a new precision treatment option ···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 181
Repotrectinib is a novel, oral, small-molecule, multi-target tyrosine kinase inhibitor (TKI) primarily used to treat advanced solid tumors harboring s···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 214
Repotrectinib, an innovative ROS1 and NTRK-targeting inhibitor, can simultaneously inhibit multiple oncogenic targets, exhibiting broad-spectrum anti-···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 179
Repotrectinib is a new generation of targeted anticancer drug developed by Bristol-Myers Squibb (BMS), providing a new option for precision treatment ···【Read More】
Update: 2026-03-03Source: Haiou HealthViews: 206
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos